BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Moodys
Harvard Business School
Medtronic
Cerilliant
McKinsey
Novartis
Queensland Health
Merck
Fish and Richardson

Generated: January 20, 2018

DrugPatentWatch Database Preview

Gd Searle Company Profile

« Back to Dashboard

Summary for Gd Searle
International Patents:94
US Patents:8
Tradenames:41
Ingredients:29
NDAs:46

Drugs and US Patents for Gd Searle

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle Llc DEMULEN 1/50-28 ethinyl estradiol; ethynodiol diacetate TABLET;ORAL-28 016936-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Gd Searle Llc CU-7 copper INTRAUTERINE DEVICE;INTRAUTERINE 017408-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-003 Sep 27, 2002 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-002 Feb 26, 1996 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Gd Searle Llc AMINOPHYLLIN aminophylline TABLET;ORAL 002386-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Gd Searle Llc NORPACE CR disopyramide phosphate CAPSULE, EXTENDED RELEASE;ORAL 018655-002 Jul 20, 1982 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-002 Sep 27, 2002 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Gd Searle Llc POTASSIUM CHLORIDE potassium chloride INJECTABLE;INJECTION 086219-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Gd Searle Llc FLAGYL metronidazole TABLET;ORAL 012623-003 Approved Prior to Jan 1, 1982 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Gd Searle Llc LIDOCAINE HYDROCHLORIDE lidocaine hydrochloride INJECTABLE;INJECTION 083135-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Gd Searle

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-002 Feb 26, 1996 ➤ Subscribe ➤ Subscribe
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-002 Sep 27, 2002 ➤ Subscribe ➤ Subscribe
Gd Searle Llc CYTOTEC misoprostol TABLET;ORAL 019268-001 Dec 27, 1988 ➤ Subscribe ➤ Subscribe
Gd Searle Llc ARTHROTEC diclofenac sodium; misoprostol TABLET, DELAYED RELEASE;ORAL 020607-001 Dec 24, 1997 ➤ Subscribe ➤ Subscribe
Gd Searle Llc CYTOTEC misoprostol TABLET;ORAL 019268-003 Sep 21, 1990 ➤ Subscribe ➤ Subscribe
Gd Searle CELEBREX celecoxib CAPSULE;ORAL 020998-001 Dec 31, 1998 ➤ Subscribe ➤ Subscribe
Gd Searle Llc CYTOTEC misoprostol TABLET;ORAL 019268-001 Dec 27, 1988 ➤ Subscribe ➤ Subscribe
Gd Searle CELEBREX celecoxib CAPSULE;ORAL 020998-002 Dec 31, 1998 ➤ Subscribe ➤ Subscribe
Gd Searle BEXTRA valdecoxib TABLET;ORAL 021341-003 Nov 16, 2001 ➤ Subscribe ➤ Subscribe
Gd Searle CELEBREX celecoxib CAPSULE;ORAL 020998-004 Dec 15, 2006 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for GD SEARLE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 50 mg/0.2 mg ➤ Subscribe 6/29/2009
➤ Subscribe Delayed-release Tablets 75 mg/0.2 mg ➤ Subscribe 11/28/2008
➤ Subscribe Capsules 50 mg ➤ Subscribe 3/21/2008
➤ Subscribe Tablets 25 mg and 50 mg ➤ Subscribe 9/27/2006

Non-Orange Book US Patents for Gd Searle

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,534,089 Uniform drug delivery therapy ➤ Subscribe
6,592,902 Controlled release eplerenone compositions ➤ Subscribe
6,863,902 Immediate release eplerenone compositions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Gd Searle Drugs

Country Document Number Estimated Expiration
Spain 2250803 ➤ Subscribe
Poland 348198 ➤ Subscribe
Japan 2002529405 ➤ Subscribe
Germany 69911240 ➤ Subscribe
Spain 2207977 ➤ Subscribe
Iceland 5953 ➤ Subscribe
Taiwan I238716 ➤ Subscribe
Germany 69709101 ➤ Subscribe
Canada 2364169 ➤ Subscribe
Argentina 028982 ➤ Subscribe
Country Document Number Estimated Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Gd Searle Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0814 Netherlands ➤ Subscribe PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
00095 Netherlands ➤ Subscribe PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
C0009 Belgium ➤ Subscribe PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
00128 Netherlands ➤ Subscribe PRODUCT NAME: VALDECOXIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH ACCEPTABEL ZOUT; REGISTRATION NO/DATE: EU/1/02/239/001 - EU/1/02/239/024, EU/1/02/242/001 - EU/1/02/242/024, EU/1/02/244/001 - EU/1/02/244/024 20030317
2006 00038 Denmark ➤ Subscribe PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
00221 Netherlands ➤ Subscribe PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
04C/008 Belgium ➤ Subscribe PRODUCT NAME: EPLERENONE; NATIONAL REGISTRATION NO/DATE: 241 IS 188 F3 20041220; FIRST REGISTRATION: NL RVG 29963 20040316
C0026 France ➤ Subscribe PRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220
C0021 Belgium ➤ Subscribe PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
C/GB99/008 United Kingdom ➤ Subscribe PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Cipla
Novartis
McKesson
Federal Trade Commission
QuintilesIMS
AstraZeneca
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot